Trial | NCT00596479  Report issue

Title

Filgrastim for the Promotion of Collateral Growth in Patients With CAD
Subcutaneous Delivery of Filgrastim (rG-CSF) for the Promotion of Collateral Growth in Patients With Coronary Artery Disease

  • Phase

    N/A

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Intervention/Treatment

    sargramostim ...

  • Study Participants

    50
The purpose of this study in humans with stable coronary artery disease (CAD) treatable by PCI (percutaneous coronary intervention) is to evaluate the safety and efficacy of subcutaneous delivery of recombinant granulocyte colony stimulating factor rG-CSF (Filgrastim, Neupogen®, Amgen Switzerland) with regard to the promotion of collateral growth.
The purpose of this study in humans with stable coronary artery disease (CAD) treatable by PCI (percutaneous coronary intervention) is to evaluate the safety and efficacy of subcutaneous delivery of recombinant granulocyte colony stimulating factor rG-CSF (Filgrastim, Neupogen®, Amgen Switzerland) with regard to the promotion of collateral growth.
Study Started
Nov 30
2004
Primary Completion
Dec 31
2007
Study Completion
Dec 31
2007
Last Update
Jun 16
2015
Estimate

Drug Filgrastim (rG-CSF)

Criteria 

Inclusion Criteria:

Age > 18 years old
1- to 3-vessel coronary artery disease (CAD)
Stable angina pectoris
At least 1 stenotic lesion suitable for PCI
No Q-wave myocardial infarction in the area undergoing CFI measurement
Written informed consent to participate in the study

Exclusion Criteria:

Patients admitted as emergencies
Acute myocardial infarction
Unstable CAD
CAD treated best by CABG
Patients with overt neoplastic disease
Patients with diabetic retinopathy
Liver or kidney disease
Pre-menopausal women
No Results Posted